Evidence map›Paper›PMID 32104357›Full record

ArticleAsian journal of pharmaceutical sciences2017

Hesperetin conjugated PEGylated gold nanoparticles exploring the potential role in anti-inflammation and anti-proliferation during diethylnitrosamine-induced hepatocarcinogenesis in rats.

Gokuladhas Krishnan, Jayakumar Subramaniyan, Pramila Chengalvarayan Subramani, Barath Muralidharan, Devaki Thiruvengadam

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Asian journal of pharmaceutical sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Liver cancer wars: plant-derived polyphenols strike back.Medical oncology (Northwood, London, England) · 2024
    Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Gokuladhas KrishnanDepartment of Biochemistry, University of Madras, Guindy Campus, Chennai 600 025, Tamilnadu, India.
Jayakumar SubramaniyanDepartment of Biochemistry, University of Madras, Guindy Campus, Chennai 600 025, Tamilnadu, India.
Pramila Chengalvarayan SubramaniDepartment of Biochemistry, University of Madras, Guindy Campus, Chennai 600 025, Tamilnadu, India.
Barath MuralidharanRagalakshmi Engineering College, Chennai 602105, Tamilnadu, India.
Devaki ThiruvengadamDepartment of Biochemistry, University of Madras, Guindy Campus, Chennai 600 025, Tamilnadu, India.
University of Madras · INRajalakshmi Engineering College

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liver cancer is the fifth most common cancer and one of the leading causes of death in the world, and second most common cause of death in men. Natural products emerge as the most enduring approaches in the development of anticancer targeting drug. Hesperetin (HP), one of the abundant flavonoids found naturally in citrus fruits, has received considerable attention in anti-cancer promotion and progression. The present study was conducted to decipher the role of 0.5 ml hesperetin conjugated gold nanoparticles (Au-mPEG

Indexed as

GlycoconjugatesGold nanoparticlesHesperetinMast cellsNF-κBPCNATNF-α

Identifiers

PMID32104357
PMCPMC7032104
OpenAlexW2612713664

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.